Diabetes Care, Vol 16, Issue 10 1347-1355, Copyright © 1993 by American Diabetes Association

ARTICLES

Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes

E Torlone, M Britta, AM Rambotti, G Perriello, F Santeusanio, P Brunetti and GB Bolli
Department of Internal Medicine and Endocrinological and Metabolic Sciences, University of Perugia, Italy.

OBJECTIVE--To determine the long-term effects of the angiotensin-converting enzyme inhibitor captopril on insulin sensitivity in subjects with type II diabetes and arterial hypertension. The chronic effects of angiotensin-converting enzyme inhibition on insulin-sensitive individuals are presently controversial. RESEARCH DESIGN AND METHODS--Sixteen subjects, with type II diabetes (on diet and/or diet plus oral hypoglycemic agents) and arterial hypertension, were studied. During a 1-mo run-in period no antihypertensive drugs were administered, but oral hypoglycemic agents were continued in subjects already in therapy. The subjects were then randomly assigned to two 3-mo treatment periods, with either captopril or placebo (single blind, cross-over design). At the end of each treatment period, insulin sensitivity was assessed by means of a euglycemic-hyperinsulinemic clamp (2 sequential steps, 2-h each, insulin infusion 0.25 and 1 mU.kg-1.min-1, steps 1 and 2, respectively), combined with infusion of [3-3H]glucose (for calculation of hepatic glucose output and peripheral glucose utilization, rates of glucose disappearance), and indirect calorimetry (for calculation of glucose oxidation, nonoxidative glucose metabolism, and lipid oxidation). The percentage of HbA1c was measured to assess long-term glycemic control. RESULTS--Comparing data at the end of placebo and captopril treatment, captopril resulted in: lower blood pressure (systolic 154 +/- 2 vs. 163 +/- 3 mmHg and diastolic 93 +/- 2 vs. 101 +/- 2 mmHg); greater insulin sensitivity in hyperglycemic conditions (total amount of insulin infused and time of insulin infusion required to reach euglycemia, 1.73 +/- 0.54 vs. 2.08 +/- 0.60 U and 58 +/- 8 vs. 70 +/- 11 min, captopril and placebo, respectively, P < 0.05); greater insulin sensitivity in euglycemic conditions at liver level (hepatic glucose output 4.11 +/- 0.55 vs. 5.2 +/- 0.4 mumol.kg-1.min-1, step 1 of the clamp), muscle level (rates of glucose disappearance 26.1 +/- 2.3 vs. 23.8 +/- 2.1 mumol.kg-1.min-1 step 2 of the clamp), primarily attributable to approximately 29% increase in nonoxidative glucose metabolism, and adipose tissue level (plasma free fatty acid 0.185 +/- 0.03 vs. 0.24 +/- 0.02 mM and lipid oxidation 1.9 +/- 0.3 vs. 2.21 +/- 0.04 mumol.kg-1.min-1 in step 1); and lower HbA1c (6.7 +/- 0.2 vs. 7.3 +/- 0.2%, P < 0.05). CONCLUSIONS--Long-term captopril administration in type II diabetic subjects improves insulin sensitivity in the postprandial state, not in the fasting state, and improves glycemic control.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Y. Wei, J. R. Sowers, S. E. Clark, W. Li, C. M. Ferrario, and C. S. Stump Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-{kappa}B activation via NADPH oxidase Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E345 - E351. [Abstract] [Full Text] [PDF]

				V. Wong, L. Szeto, K. Uffelman, I G. Fantus, and G. F Lewis Enhancement of muscle glucose uptake by the vasopeptidase inhibitor, omapatrilat, is independent of insulin signaling and the AMP kinase pathway. J. Endocrinol., August 1, 2006; 190(2): 441 - 450. [Abstract] [Full Text] [PDF]

				T.-J. Hsieh, P. Fustier, C.-C. Wei, S.-L. Zhang, J. G Filep, S.-S. Tang, J. R Ingelfinger, I G. Fantus, P. Hamet, and J. S D Chan Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells J. Endocrinol., December 1, 2004; 183(3): 535 - 550. [Abstract] [Full Text] [PDF]

				Y. Shimoni, M. Chuang, E. D. Abel, and David. L. Severson Gender-dependent attenuation of cardiac potassium currents in type 2 diabetic db/db mice J. Physiol., March 1, 2004; 555(2): 345 - 354. [Abstract] [Full Text] [PDF]

				A. K. Trauernicht, H. Sun, K. P. Patel, and W. G. Mayhan Enalapril Prevents Impaired Nitric Oxide Synthase-Dependent Dilatation of Cerebral Arterioles in Diabetic Rats Stroke, November 1, 2003; 34(11): 2698 - 2703. [Abstract] [Full Text] [PDF]

				M. Igarashi, A. Hirata, H. Yamaguchi, H. Tsuchiya, H. Ohnuma, M. Tominaga, M. Daimon, and T. Kato Candesartan Inhibits Carotid Intimal Thickening and Ameliorates Insulin Resistance in Balloon-Injured Diabetic Rats Hypertension, December 1, 2001; 38(6): 1255 - 1259. [Abstract] [Full Text] [PDF]

				I. Gustafsson, C. Torp-Pedersen, L. Kober, F. Gustafsson, P. Hildebrandt, and on behalf of the Trace Study Group Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction J. Am. Coll. Cardiol., July 1, 1999; 34(1): 83 - 89. [Abstract] [Full Text] [PDF]

				E. Bonora, G. Targher, M. Alberiche, R. C. Bonadonna, F. Saggiani, M. B. Zenere, S. Uleri, and M. Muggeo Effect of Chronic Treatment with Lacidipine or Lisinopril on Intracellular Partitioning of Glucose Metabolism in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1544 - 1550. [Abstract] [Full Text]

				R. W. Nesto and S. Zarich Acute Myocardial Infarction in Diabetes Mellitus : Lessons Learned From ACE Inhibition Circulation, January 13, 1998; 97(1): 12 - 15. [Full Text] [PDF]

				J. G. Spangler, R. A. Bell, J. H. Summerson, and J. C. Konen Hyperinsulinemia in Hypertension: Associations With Race, Abdominal Obesity, and Hyperlipidemia Arch Fam Med, January 1, 1998; 7(1): 53 - 56. [Abstract] [Full Text] [PDF]

				T. Rosenthal, Y. Erlich, E. Rosenmann, and A. Cohen Effects of Enalapril, Losartan, and Verapamil on Blood Pressure and Glucose Metabolism in the Cohen-Rosenthal Diabetic Hypertensive Rat Hypertension, June 1, 1997; 29(6): 1260 - 1264. [Abstract] [Full Text]